A sustained-release external patch

Abstract

The application relates to the technical field of medical supplies, in particular to a slow-release external-use patch, which comprises a protective layer, a drug carrying layer, an adhesive layer and a release layer; the drug carrying layer is arranged on the protective layer; the drug carrying layer comprises an aerogel cloth substrate; the drug carrying layer is arranged between the protective layer and the adhesive layer; and the release layer is arranged on the side of the adhesive layer away from the drug carrying layer. The slow-release external-use patch provided by the application uses the aerogel cloth substrate as the main body of the traditional Chinese medicine drug carrying body, compared with the oiliness matrix used by the traditional plaster, the high specific surface area and the three-dimensional porous network structure of the gel material of the aerogel cloth substrate are utilized to realize efficient drug carrying, slow release and optimization of air permeability, and the utilization rate of the drug is significantly improved.

Description

Technical Field

[0001] This application relates to the field of medical supplies technology, and in particular to a sustained-release topical patch. Background Technology

[0002] Currently, traditional medicated plasters typically use an oil-based base, which hinders the absorption of the active ingredients of the medicine through the skin, resulting in low drug utilization. Long-term use may also cause adverse reactions such as skin stuffiness and allergies. Traditional medicated plasters also have poor breathability, leading to increased skin discomfort. Utility Model Content

[0003] The purpose of this application is to provide a sustained-release external patch to address, to some extent, the technical problem of low drug utilization rate in traditional medicated plasters in the prior art.

[0004] This application provides a sustained-release topical patch, comprising: Protective layer; A drug carrier layer is disposed on the protective layer; the drug carrier layer includes an aerogel fabric substrate. An adhesive layer, wherein the drug carrier layer is disposed between the protective layer and the adhesive layer; A release layer is disposed on the side of the adhesive layer opposite to the drug carrier layer.

[0005] In the above technical solution, the specific surface area of ​​the aerogel fabric substrate is further defined as 800~1200 m². 2 / g, the porosity of the aerogel fabric substrate is ≥92%, and the pore size of the aerogel fabric substrate is 50-500 nm. In any of the above technical solutions, the thickness of the drug carrier layer is further 0.3mm~1mm.

[0006] In any of the above technical solutions, the drug carrier layer is further provided with limiting grooves, and the number of limiting grooves is multiple, with the multiple limiting grooves arranged at intervals.

[0007] In any of the above technical solutions, the drug carrier layer is further provided with a plurality of limiting holes, and the plurality of limiting holes are spaced apart.

[0008] In any of the above technical solutions, the protective layer is further described as a non-woven fabric layer, and the air permeability of the protective layer is ≥3000 g / m·24h.

[0009] In any of the above technical solutions, the adhesive layer further comprises medical silicone pressure-sensitive adhesive; the adhesive layer is in the form of a mesh.

[0010] In any of the above technical solutions, the release layer further includes an anti-adhesion paper that covers the adhesive layer.

[0011] In any of the above technical solutions, the sustained-release topical patch further includes a transdermal enhancement layer, which is disposed between the drug carrier layer and the adhesive layer; the transdermal enhancement layer includes a gelatin hydrogel membrane.

[0012] In any of the above technical solutions, the thickness of the gelatin hydrogel film is further 50-100 μm.

[0013] Compared with the prior art, the beneficial effects of this application are as follows: The sustained-release topical patch provided in this application includes: a protective layer; a drug carrier layer disposed on the protective layer; the drug carrier layer includes an aerogel fabric substrate; an adhesive layer disposed between the protective layer and the adhesive layer; and a release layer disposed on the side of the adhesive layer opposite to the drug carrier layer.

[0014] The sustained-release external patch provided in this application uses an aerogel cloth substrate as the main carrier of traditional Chinese medicine. Compared with the oily matrix used in traditional plasters, the high specific surface area and three-dimensional porous network structure of the gel material in the aerogel cloth substrate achieve efficient drug loading, sustained release and optimized breathability, significantly improving the utilization rate of the drug. Attached Figure Description To more clearly illustrate the technical solutions in the specific embodiments of this application or the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this application. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0015] Figure 1 This is a schematic diagram of the structure of the sustained-release topical patch provided in the embodiments of this application; Figure 2 This is a schematic diagram of the structure of the drug carrier layer of the sustained-release topical patch provided in the embodiments of this application; Figure 3 Another schematic diagram of the drug carrier layer of the sustained-release topical patch provided in the embodiments of this application; Figure 4 This is another schematic diagram of the drug carrier layer of the sustained-release topical patch provided in the embodiments of this application.

[0016] Figure label: 10-Protective layer, 20-Drug carrier layer, 30-Transdermal facilitator layer, 40-Adhesive layer, 50-Release layer, 60-Limiting groove, 70-Limiting hole. Detailed Implementation

[0017] The technical solutions of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are some embodiments of this application, but not all embodiments.

[0018] The components of the embodiments of this application described and shown in the accompanying drawings can be arranged and designed in a variety of different configurations. Therefore, the following detailed description of the embodiments of this application provided in the drawings is not intended to limit the scope of the claimed application, but merely to illustrate selected embodiments of the application.

[0019] Based on the embodiments in this application, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this application.

[0020] In the description of this application, it should be noted that the terms "center," "upper," "lower," "left," "right," "vertical," "horizontal," "inner," and "outer," etc., indicate the orientation or positional relationship based on the orientation or positional relationship shown in the accompanying drawings. They are used only for the convenience of describing this application and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation. Therefore, they should not be construed as limitations on this application. Furthermore, the terms "first," "second," and "third" are used for descriptive purposes only and should not be construed as indicating or implying relative importance.

[0021] In the description of this application, it should be noted that, unless otherwise expressly specified and limited, the terms "installation," "connection," and "linking" should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral connection; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or an indirect connection through an intermediate medium; and they can refer to the internal connection between two components. Those skilled in the art can understand the specific meaning of the above terms in this application according to the specific circumstances.

[0022] The following reference Figures 1 to 4 The sustained-release topical patch described in the embodiments of this application.

[0023] See Figures 1 to 4As shown, an embodiment of this application provides a sustained-release topical patch. This sustained-release topical patch includes a protective layer 10, a drug-carrying layer 20, an adhesive layer 40, and a release layer 50, arranged layer by layer. The drug-carrying layer 20 is disposed on the protective layer 10, and the protective layer 10 protects the drug-carrying layer 20. The drug-carrying layer 20 includes an aerogel fabric substrate and a drug disposed on the aerogel fabric substrate. The adhesive layer 40 is disposed on the side of the drug-carrying layer 20 opposite to the protective layer 10, and is used to adhere the sustained-release topical patch to human skin so that the drug can act on the human body through sustained release. The release layer 50 is disposed on the surface of the adhesive layer 40 opposite to the drug-carrying layer 20. Before use, the release layer 50 covers the adhesive layer 40 to protect it.

[0024] It should be noted that the aerogel substrate in this embodiment can be silane-modified cellulose aerogel, silica aerogel, etc., which are common in the prior art. The drug can be placed on the aerogel substrate by coating it or embedding it in the aerogel substrate.

[0025] As can be seen, the sustained-release external patch provided in this application uses an aerogel cloth substrate as the main carrier of traditional Chinese medicine. Compared with the oily matrix used in traditional plasters, it utilizes the high specific surface area and three-dimensional porous network structure of the gel material in the aerogel cloth substrate to achieve efficient drug loading, sustained release and optimized air permeability, significantly improving the utilization rate of the drug.

[0026] In addition, the porosity of the aerogel is 80% higher than that of the traditional rubber matrix, and clinical tests have shown that the rate of adverse skin reactions is reduced by 67%, which significantly improves the comfort of using this sustained-release topical patch.

[0027] In one embodiment of this application, preferably, the sustained-release topical patch further includes a transdermal enhancement layer 30, which is disposed between the drug carrier layer 20 and the adhesive layer 40; the transdermal enhancement layer 30 includes a gelatin hydrogel film. In one embodiment of this application, preferably, the thickness of the gelatin hydrogel film is 50-100 μm. In this embodiment, the transdermal enhancement layer 30 is disposed between the drug carrier layer 20 and the adhesive layer 40. This sustained-release topical patch has a five-layer composite structure, such as... Figure 1 As shown, the layers are arranged in sequence as follows: protective layer 10, drug carrier layer 20, transdermal facilitator layer 30, adhesive layer 40, and release layer 50. The transdermal facilitator layer 30 is composed of a gelatin hydrogel membrane commonly used in the prior art. The thickness of the gelatin hydrogel membrane is preferably 50-100μm, making the transdermal facilitator layer 30 a moisture-sensitive and breathable facilitator layer. When the skin sweats more, the breathability automatically increases, thereby improving the comfort of the skin. In one embodiment of this application, preferably, the specific surface area of ​​the aerogel fabric substrate is 800~1200m². 2 / g, the porosity of the aerogel cloth substrate is ≥92%, and the pore size of the aerogel cloth substrate is 50-500 nm.

[0028] In one embodiment of this application, preferably, the thickness of the drug carrier layer 20 is 0.3 mm to 1 mm.

[0029] The properties of the drug carrier layer 20 are determined by the type of aerogel selected. In this embodiment, an aerogel with the above parameters is selected to ensure the drug release effect.

[0030] In addition, aerogel has a stable structure and certain swelling properties, which can help absorb wound exudate and will not degrade due to swelling, making it a potential dressing. Moreover, when aerogel comes into contact with blood, it forms a fibrin network, which can block and absorb blood, and can also activate platelets, causing them to coagulate quickly, thereby achieving a good hemostatic effect.

[0031] It should be noted that during the production process, the aerogel fabric substrate can be cut into different thicknesses to be compatible with existing sustained-release topical patch production lines and adapt to traditional processes, without the need for additional preparation or production line upgrades.

[0032] In one embodiment of this application, preferably, the drug carrier layer 20 is provided with a limiting groove 60, and the number of limiting grooves 60 is multiple, with the multiple limiting grooves 60 arranged at intervals. In this embodiment, the limiting groove 60 is elongated, and multiple limiting grooves 60 are of the same length and are arranged in parallel at equal intervals. The limiting grooves 60 can penetrate both sides of the drug carrier layer 20, or the depth of the limiting groove 60 can be less than the thickness of the drug carrier layer 20, in which case the opening of the limiting groove 60 faces the release layer 50. The multiple limiting grooves 60 can be of the same length, and the length of any one of the multiple limiting grooves 60 can extend along the width direction of the drug carrier layer 20. Alternatively, the lengths of the multiple limiting grooves 60 are not entirely the same, and each limiting groove 60 extends along the diagonal line connecting the drug carrier layer 20.

[0033] In one embodiment of this application, preferably, the drug carrier layer 20 is provided with a plurality of limiting holes 70, and the plurality of limiting holes 70 are spaced apart. In this embodiment, multiple limiting holes 70 are distributed in a clustered matrix. The limiting holes 70 can penetrate both sides of the drug carrier layer 20, or the depth of the limiting holes 70 is less than the thickness of the drug carrier layer 20. In this case, the opening of the limiting holes 70 is set towards the release layer 50.

[0034] The limiting hole 70 and the limiting groove 60 can be provided simultaneously or selectively. By providing the limiting hole 70 and / or the limiting groove 60, this sustained-release external patch can have the following advantages: Firstly, it can improve drug adsorption efficiency: by designing slots or clusters, the contact area between the drug and the aerogel substrate can be increased. In particular, the way the drug is coated on the aerogel substrate can increase the amount of drug adsorption.

[0035] In addition, the limiting design can prevent drug particles from shifting or falling off due to external forces during the adsorption process, ensuring that the drug is stably adsorbed on the aerogel substrate.

[0036] Secondly, it can improve the accuracy of drug release: when the drug is filled into the limiting groove 60 or the limiting hole 70, or when the drug is coated on the aerogel cloth substrate, the drug thickness in the limiting groove 60 and the limiting hole 70 will be greater than the drug thickness in other locations. The limiting design can control the distribution of the drug in the aerogel cloth, so that it gathers in a specific area, thereby achieving precise control of drug release.

[0037] Furthermore, by adjusting the size and distribution of the slots or cluster sites, the drug release rate can be adjusted to meet different treatment needs.

[0038] Thirdly, it can improve drug stability: the limiting design can protect drug particles and prevent them from breaking or deteriorating due to external forces during storage and use.

[0039] Protecting the drug by using slots or clusters of sites can extend its shelf life and improve its stability.

[0040] Fourthly, enhancing the mechanical properties of aerogel fabric: the limiting design can enhance the mechanical properties of the aerogel fabric base, making it more robust and less prone to deformation or breakage during use.

[0041] The compressive and tensile strength of the aerogel fabric substrate can be improved by the support of grooves or clusters.

[0042] In one embodiment of this application, preferably, the protective layer 10 is a non-woven fabric layer, and the air permeability of the protective layer 10 is ≥ By optimizing the structure of the protective layer 10, it is made to have better breathability, thereby further improving the comfort of this sustained-release topical patch. In one embodiment of this application, preferably, the adhesive layer 40 comprises medical silicone pressure-sensitive adhesive; the adhesive layer 40 is in the form of a mesh. In this embodiment, the adhesive layer 40 has a hollowed-out mesh structure made of medical silicone pressure-sensitive adhesive commonly used in the prior art. While ensuring the adhesion effect, the hollowed-out design of the adhesive layer 40 can prevent the hair follicles under the application area from being completely blocked when the slow-release topical patch is used.

[0043] Preferably, the adhesion layer 40 has a coverage of about 60%, which ensures adhesion and improves the comfort of the sustained-release topical patch.

[0044] In one embodiment of this application, preferably, the release layer 50 includes a release liner that covers the adhesive layer 40. In this embodiment, the adhesive layer 40 is covered with release paper to protect the adhesive layer 40 and the drug carrier layer 20 before the use of this sustained-release external patch, so as to prevent the viscosity of the adhesive layer 40 from decreasing and to prevent drug loss.

[0045] In summary, the sustained-release external patch provided in this application uses an aerogel fabric substrate as the main carrier of traditional Chinese medicine. Compared with the oily matrix used in traditional plasters, it utilizes the high specific surface area and three-dimensional porous network structure of the gel material in the aerogel fabric substrate to achieve efficient drug loading, sustained release, and optimized breathability, thereby significantly improving the utilization rate of the drug. Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of this application, and are not intended to limit them. Although this application has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of this application.

Claims

1. A sustained-release topical patch, characterized in that, include: Protective layer; A drug carrier layer, wherein the drug carrier layer is disposed on the protective layer; The drug-carrying layer includes an aerogel fabric substrate; An adhesive layer, wherein the drug carrier layer is disposed between the protective layer and the adhesive layer; A release layer is disposed on the side of the adhesive layer opposite to the drug carrier layer.

2. The sustained-release topical patch according to claim 1, characterized in that, The specific surface area of ​​the aerogel fabric substrate is 800~1200 m². 2 / g, the porosity of the aerogel fabric substrate is ≥92%, and the pore size of the aerogel fabric substrate is 50-500nm.

3. The sustained-release topical patch according to claim 1, characterized in that, The thickness of the drug carrier layer is 0.3 mm to 1 mm.

4. The sustained-release topical patch according to claim 1, characterized in that, The drug carrier layer has multiple limiting grooves, which are spaced apart.

5. The sustained-release topical patch according to claim 1, characterized in that, The drug carrier layer is provided with multiple limiting holes, which are spaced apart.

6. The sustained-release topical patch according to claim 1, characterized in that, The protective layer is a non-woven fabric layer, and the air permeability of the protective layer is ≥3000 g / m·24h.

7. The sustained-release topical patch according to claim 1, characterized in that, The adhesive layer comprises medical-grade silicone pressure-sensitive adhesive; the adhesive layer is in the form of a mesh.

8. The sustained-release topical patch according to claim 1, characterized in that, The release layer includes a release liner that covers the adhesive layer.

9. The sustained-release topical patch according to any one of claims 1 to 8, characterized in that, The sustained-release topical patch further includes a transdermal enhancement layer disposed between the drug carrier layer and the adhesive layer; the transdermal enhancement layer includes a gelatin hydrogel membrane.

10. The sustained-release topical patch according to claim 9, characterized in that, The thickness of the gelatin hydrogel film is 50-100 μm.

Images